Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K
Tsukuba Research Laboratories, Eisai Company, Ltd., Ibaraki, Japan.
J Med Chem. 1995 Nov 24;38(24):4821-9. doi: 10.1021/jm00024a009.
Following the discovery of a new series of anti-acetylcholinesterase (anti-AChE) inhibitors such as 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine (1), we reported that its rigid analogue, 1-benzyl-4-(2-isoindolin-2-ylethyl)piperidine (5), had more potent activity. We have extended the structure-activity relationship (SAR) study for the rigid analogue and found that the 2-isoindoline moiety in compound 5 can be replaced with a indanone moiety (8) without a major loss in potency. Among the indanone derivatives, 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine (13e) (E2020) (IC50 = 5.7 nM) was found to be one of the most potent anti-AChE inhibitors. Compound 13e showed a selective affinity 1250 times greater for AChE than for butyrylcholinesterase. In vivo studies demonstrated that 13e has a longer duration of action than physostigmine at a dose of 5 mg/kg (po) and produced a marked and significant increase in acetylcholine content in rat cerebral cortex. We report the synthesis, SAR, and a proposed hypothetical binding site of 13e (E2020).
在发现了一系列新的抗乙酰胆碱酯酶(anti-AChE)抑制剂,如1-苄基-4-[2-(N-苯甲酰氨基)乙基]哌啶(1)之后,我们报道其刚性类似物1-苄基-4-(2-异吲哚啉-2-基乙基)哌啶(5)具有更强的活性。我们对该刚性类似物进行了构效关系(SAR)研究扩展,发现化合物5中的2-异吲哚啉部分可以被茚满酮部分(8)取代,而活性不会有太大损失。在茚满酮衍生物中,1-苄基-4-[(5,6-二甲氧基-1-氧代茚满-2-基)甲基]哌啶(13e)(E2020)(IC50 = 5.7 nM)被发现是最有效的抗AChE抑制剂之一。化合物13e对AChE的选择性亲和力比对丁酰胆碱酯酶高1250倍。体内研究表明,在5 mg/kg(口服)剂量下,13e的作用持续时间比毒扁豆碱长,并且使大鼠大脑皮层中的乙酰胆碱含量显著增加。我们报道了13e(E2020)的合成、构效关系以及一个推测的假设结合位点。